Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Arena Pharmaceuticals (ARNA), VIVUS (VVUS), Amarin (AMRN) See Stocks Tied Together Again

Three pharmaceutical companies – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS) and Amarin Corporation, PLC (NASDAQ:AMRN) – have been intrinsically linked in the markets the last few weeks, as each of the companies have recently received FDA approval for their drugs, with the former two companies in a direct head-to-head battle over weight-loss pills.


The companies all seem to have their stocks rise and fall on each other’s news, and today’s news might be another example of that. VIVUS, Inc. (NASDAQ:VVUS) stock is up more than 9 percent today following a report that Lazard Capital Markets was upgrading VIVUS stock to a “buy” rating from “neutral,” saying the firm’s current patent battle with Johnson & Johnson (NYSE:JNJ) will not have an adverse affect on the sale of weight-loss drug Qsymia, over which the patent disputes has evolved. The Lazard analysis report indicated that the possible resolution for the dispute with Johnson & Johnson (NYSE:JNJ) would be for VIVUS, Inc. (NASDAQ:VVUS) to send royalties for the sales of Qsymia, which contains the patent-disputed drug, topiramate.

This contrasts with an earlier report by Citron Research that doubted Qsymia’s overall success not only because of the patent litigation bt also because of safety and effectiveness concerns surrounding the drug.

In midafternoon trading Tuesday, VIVUS stock was up more than 9 percent to $23.20 a share.

And as it seems that the very same FDA aproved all thee companies’ drugs, if one company is seen to have positive momentum in its future sales of its drugs, then the same thgouth goes to the other two companies. As a result of this report, not only has VIVUS Inc. (NASDAQ:VVUS) specifically benefitted, but ti appears the two rivals have benefited as well. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock is up nearly 3 percent to $7.40 a share, while Amarin Corporation, PLC (NASDAQ:AMRN) is up nearly 4 percent to $11.60.

And we might want to get used to this, at least for a few more weeks. It’s possible that investors won’t be able to distinguish between these companies until their drugs actually reach market and investors start to see the competition unfold and which company will be able to more effectively monetize all their research and development. Only at point-of-sale may distinctions truly be made – unless one of the companies gets singled out one way or another, before then. Until then, the markets will likely see Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS) and Amarin Corporation, PLC (NASDAQ:AMRN) as three peas in the same pharmaceutical industry pod.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.